Prothena Shares Down; Parkinson's Disease Study Doesn't Meet Primary Objective
April 22 2020 - 10:12AM
Dow Jones News
By Michael Dabaie
Prothena Corp. PLC shares were down 19% to $9.67 in early
trading.
The clinical-stage neuroscience company said Roche provided an
update on Part 1 of the Phase 2 PASADENA study of prasinezumab in
patients with early Parkinson's disease.
Prothena said the study didn't meet the primary objective, but
showed signals of efficacy. In 2013, Prothena and Roche entered
into a collaboration to develop and commercialize antibodies that
target alpha-synuclein, including prasinezumab.
Based on ongoing evaluation of the data, including potential
discussions with health authorities, a further update on
prasinezumab is expected later this year.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
April 22, 2020 09:57 ET (13:57 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024
